# US 2025/0186566 A1 · Cell-based vaccines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0186566 A1
- Document ID: US20250186566A1
- Status: Published application
- Kind: A1
- Application number: 18/977,008
- Filed: 2024-12-11
- Published: 2025-06-12
- Earliest claimed: 2023-12-11
- Assignees: Arkea Bio Corp.
- Applicants: Arkea Bio Corp.
- Inventors: Matthew Dunn; Brigid Arciero; Colin South; Kristin Adolfsen; Jeff Bickmeier; John Sullivan; Sara Kimler; Lauren Fitch; Joseph Koos; Laura Holland; Taylor Falk; James Spoonamore; Zeljko Radulovic; Caitlin Allen; Anna Li; Alexander Hsu; Sara Tabandeh; Frederick Richard Kearney
- Web page: https://patentgrep.com/patent/US20250186566A1

## CPC

- A61K 39/0001: {Archaeal antigens}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 37/04: Immunostimulants
- A61K 2039/521: {inactivated (killed)}
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55522: {Cytokines; Lymphokines; Interferons}
- A61K 2039/55544: {Bacterial toxins}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/55577: {Saponins; Quil A; QS21; ISCOMS}
- A61K 2039/575: {humoral response}
- A61K 2039/6081: {Albumin; Keyhole limpet haemocyanin [KLH]}
- A61K 2039/70: {Multivalent vaccine}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to cell-based vaccine compositions and methods that reduce methane and/or hydrogen production in animals. The present invention relates to the treatment of diseases that are associated with methanogens. The present invention also relates to methods of growing hydrogenotrophs in safe anaerobic conditions.

## Claims

### Claim at position 1

1-227. (canceled)

### Claim 228

A vaccine composition comprising cells and/or cell parts of at least one methanogen, wherein the at least one methanogen comprises Methanobrevibacter gottschalkii.

### Claim 229 (depends on 228)

The vaccine composition of claim 228, wherein the cells and/or cell parts are killed, fixed, and/or irradiated.

### Claim 230 (depends on 228)

The vaccine composition of claim 228, wherein the cells and/or cell parts are:
(a) killed by heat, steam, freezing, or sonicated;
(b) fixed by formaldehyde or formalin; and/or
(c) irradiated by UV or gamma irradiation.

### Claim 231 (depends on 228)

The vaccine composition of claim 228, wherein at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of the cells and/or cell parts are cells.

### Claim 232 (depends on 228)

The vaccine composition of claim 228, wherein the vaccine composition comprises at least about 106, 107, 108, 109, or 1010 cells per mL; and/or no more than about 107, 108, 109, 1010, 1011, or 1012 cells per mL.

### Claim 233 (depends on 228)

The vaccine composition of claim 228, wherein the vaccine composition comprises:
(a) at least about 106 but no more than about 1012 cells per mL;
(b) at least about 108 but no more than about 1012 cells per mL;
(c) at least about 108 but no more than about 1011 cells per mL; or
(d) at least about 108 but no more than about 1010 cells per mL.

### Claim 234 (depends on 228)

The vaccine composition of claim 228, wherein the vaccine composition comprises:
(a) at least about 0.2, 0.4, 0.6, 0.8, 1, 1.2, 1.4, 1.6, 1.8, 2, or 4 mg of total proteins; and/or
(b) no more than about 0.4, 0.6, 0.8, 1, 1.2, 1.4, 1.6, 1.8, 2, 4, 6, 8, or 10 mg of total proteins.

### Claim 235 (depends on 228)

The vaccine composition of claim 228, wherein the vaccine composition comprises:
(a) at least about 0.2 mg but no more than about 10 mg of total protein; or
(b) at least about 0.6 mg but no more than about 5 mg of total protein.

### Claim 236 (depends on 228)

The vaccine composition of claim 228, wherein the cells and/or cell parts are lyophilized.

### Claim 237 (depends on 228)

The vaccine composition of claim 228, wherein the vaccine composition is a pharmaceutical composition.

### Claim 238 (depends on 237)

The vaccine composition of claim 237, wherein the pharmaceutical composition comprises at least one carrier, at least one excipient, at least one cryoprotectant, and/or at least one inactive ingredient.

### Claim 239 (depends on 228)

The vaccine composition of claim 228, wherein wherein the vaccine composition comprises at least one adjuvant.

### Claim 240 (depends on 239)

The vaccine composition of claim 239, wherein the at least one adjuvant comprises:
(a) inorganic salts, preferably aluminum and calcium salts;
(b) an oil emulsion;
(c) saponins;
(d) lipid or liposomes
(e) an immune-stimulating complex;
(f) a carrier protein (e.g., keyhole limpet hemocyanin (KLH), optionally conjugated to cells and/or cell parts);
(g) a bacterial product or derivatives thereof (e.g., bacterial toxins, lipopolysaccharide, etc.);
(h) a cytokine; or
(i) any combination of two or more selected from (a)-(h).

### Claim 241 (depends on 239)

The vaccine composition of claim 239, wherein the at least one adjuvant comprises Complete Freund's adjuvant, Incomplete Freund's adjuvant, Montanide ISA70, Montanide ISA61, Saponin, chitosan thermogel, lipid, monophosphoryl lipid A, a lipid nanoparticle/cationic liposome adjuvant, Emulsigen-D, Emulsigen, Emulsigen-P, Polygen, ENABL 06, Montainde ISA 201, Montanide Gel 02, or any combination of two or more thereof.

### Claim 242 (depends on 228)

The vaccine composition of claim 228, wherein the at least one methanogen further comprises Methanobrevibacter ruminantium.

### Claim 243 (depends on 242)

The vaccine composition of claim 242, wherein the ratio of Methanobrevibacter ruminantium to Methanobrevibacter gottschalkii is at least about 1:9, 2:8, 3:7, 4:6, 5:5, 6:4, 7:3, 8:2, or 9:1 by cell number.

### Claim 244 (depends on 242)

The vaccine composition of claim 242, wherein the at least one methanogen consists of Methanobrevibacter gottschalkii and Methanobrevibacter ruminantium.

### Claim 245 (depends on 228)

The vaccine composition of claim 228, wherein Methanobrevibacter gottschalkii is Methanobrevibacter gottschalkii DSM11977.

### Claim 246 (depends on 242)

The vaccine composition of claim 242, wherein Methanobrevibacter ruminantium is Methanobrevibacter ruminantium M1.

### Claim 247 (depends on 228)

A method of inducing an immune response against at least one methanogen in a subject, the method comprising administering to the subject the vaccine of claim 228.

### Claim 248 (depends on 228)

A method of reducing the activity, number, and/or type of methanogens in a digestive tract of a subject, the method comprising administering to the subject the vaccine composition of claim 228.
